506 related articles for article (PubMed ID: 18515791)
1. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase 2 induces epithelial-mesenchymal transition in proximal tubules from the luminal side and progresses fibrosis in mineralocorticoid/salt-induced hypertensive rats.
Iwazu Y; Muto S; Hirahara I; Fujisawa G; Takeda S; Kusano E
J Hypertens; 2011 Dec; 29(12):2440-53. PubMed ID: 22045122
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats.
Schupp N; Kolkhof P; Queisser N; Gärtner S; Schmid U; Kretschmer A; Hartmann E; Oli RG; Schäfer S; Stopper H
FASEB J; 2011 Mar; 25(3):968-78. PubMed ID: 21135038
[TBL] [Abstract][Full Text] [Related]
4. Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes.
Amador CA; Barrientos V; Peña J; Herrada AA; González M; Valdés S; Carrasco L; Alzamora R; Figueroa F; Kalergis AM; Michea L
Hypertension; 2014 Apr; 63(4):797-803. PubMed ID: 24420551
[TBL] [Abstract][Full Text] [Related]
5. Rosiglitazone prevents the progression of renal injury in DOCA-salt hypertensive rats.
Bae EH; Kim IJ; Ma SK; Kim SW
Hypertens Res; 2010 Mar; 33(3):255-62. PubMed ID: 20057489
[TBL] [Abstract][Full Text] [Related]
6. Cardiac sympathetic hyperinnervation in deoxycorticosterone acetate-salt hypertensive rats.
Lee TM; Chen CC; Chang NC
Clin Sci (Lond); 2012 Oct; 123(7):445-57. PubMed ID: 22507072
[TBL] [Abstract][Full Text] [Related]
7. Statin treatment reduces glomerular inflammation and podocyte damage in rat deoxycorticosterone-acetate-salt hypertension.
Hartner A; Klanke B; Cordasic N; Amann K; Schmieder RE; Veelken R; Hilgers KF
J Hypertens; 2009 Feb; 27(2):376-85. PubMed ID: 19226708
[TBL] [Abstract][Full Text] [Related]
8. Emblica officinalis exerts antihypertensive effect in a rat model of DOCA-salt-induced hypertension: role of (p) eNOS, NO and oxidative stress.
Bhatia J; Tabassum F; Sharma AK; Bharti S; Golechha M; Joshi S; Sayeed Akhatar M; Srivastava AK; Arya DS
Cardiovasc Toxicol; 2011 Sep; 11(3):272-9. PubMed ID: 21748534
[TBL] [Abstract][Full Text] [Related]
9. Antihypertensive and cardiorenal protective effects of SM-368229, a novel mineralocorticoid receptor antagonist, in aldosterone/salt-treated rats.
Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
Pharmacology; 2012; 89(1-2):44-52. PubMed ID: 22302095
[TBL] [Abstract][Full Text] [Related]
10. Heme arginate therapy enhanced adiponectin and atrial natriuretic peptide, but abated endothelin-1 with attenuation of kidney histopathological lesions in mineralocorticoid-induced hypertension.
Ndisang JF; Jadhav A
J Pharmacol Exp Ther; 2010 Jul; 334(1):87-98. PubMed ID: 20392817
[TBL] [Abstract][Full Text] [Related]
11. Regression of existing glomerulosclerosis by inhibition of aldosterone.
Aldigier JC; Kanjanbuch T; Ma LJ; Brown NJ; Fogo AB
J Am Soc Nephrol; 2005 Nov; 16(11):3306-14. PubMed ID: 16192423
[TBL] [Abstract][Full Text] [Related]
12. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
[TBL] [Abstract][Full Text] [Related]
13. Dietary chloride does not correlate with urinary thromboxane in deoxycorticosterone acetate-treated rats.
Theriot JA; Passmore JC; Jimenez AE; Fleming JT
J Lab Clin Med; 2000 Jun; 135(6):493-7. PubMed ID: 10850649
[TBL] [Abstract][Full Text] [Related]
14. Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats.
Jin L; Beswick RA; Yamamoto T; Palmer T; Taylor TA; Pollock JS; Pollock DM; Brands MW; Webb RC
J Physiol Pharmacol; 2006 Sep; 57(3):343-57. PubMed ID: 17033089
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
Brown L; Duce B; Miric G; Sernia C
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats.
Diaz J; Ni W; Thompson J; King A; Fink GD; Watts SW
J Pharmacol Exp Ther; 2008 Jun; 325(3):1031-8. PubMed ID: 18305011
[TBL] [Abstract][Full Text] [Related]
17. Hypertension-induced renal fibrosis and spironolactone response vary by rat strain and mineralocorticoid receptor gene expression.
Cavallari LH; Fashingbauer LA; Camp JR; King ST; Geenen DL
J Renin Angiotensin Aldosterone Syst; 2008 Sep; 9(3):146-53. PubMed ID: 18957385
[TBL] [Abstract][Full Text] [Related]
18. Digoxin amplifies the effects of deoxycorticosterone acetate (DOCA) in intact water-drinking rats: implications for the mechanism of DOCA hypertension?
Li M; Martin A; Liu DT; Whitworth JA
J Hypertens; 1994 May; 12(5):569-76. PubMed ID: 7930557
[TBL] [Abstract][Full Text] [Related]
19. Na/H exchange isoform 1 is involved in mineralocorticoid/salt-induced cardiac injury.
Fujisawa G; Okada K; Muto S; Fujita N; Itabashi N; Kusano E; Ishibashi S
Hypertension; 2003 Mar; 41(3):493-8. PubMed ID: 12623949
[TBL] [Abstract][Full Text] [Related]
20. Effect of exercise training on liver antioxidant status of deoxycorticosterone acetate salt induced hypertensive rats.
Elhaïmeur F; Courderot-Masuyer C; Nicod L; Bobillier-Chaumont S; Robin S; Richert L; Berthelot A
Can J Physiol Pharmacol; 2003 May; 81(5):469-75. PubMed ID: 12774853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
